Abstract
Background
Hypercholesterolemia is a risk factor for coronary artery disease, yet is associated with lower risk of adverse outcomes in patients with acute coronary syndromes (ACS).
Hypothesis
We explored this paradox in 84 429 patients with non‐ST‐segment elevation ACS in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines registry.
Methods
We examined the association between a history of hypercholesterolemia and in‐hospital mortality after adjusting for clinical covariates. After excluding patients with previously diagnosed hypercholesterolemia, we repeated the analysis, examining the association between newly diagnosed hypercholesterolemia (in‐hospital low‐density lipoprotein cholesterol [LDL‐C] ≥ 100 mg/dL) and mortality.
Results
A history of hypercholesterolemia was associated with lower in‐hospital mortality (unadjusted odds ratio [OR]: 0.58; 95% confidence interval [CI]: 0.55, 0.62). This protective association persisted after adjusting for baseline characteristics (OR: 0.71; 95% CI: 0.66, 0.76) and prior statin use (OR: 0.74; 95% CI: 0.68, 0.80). Among 22 711 patients with no history of hypercholesterolemia, 12 809 had a new in‐hospital diagnosis of hypercholesterolemia. Unadjusted mortality in these patients was lower than among those with normal LDL levels (OR: 0.58; 95% CI: 0.50, 0.67); however, this difference was not significant after multivariable adjustment (OR: 0.86; 95% CI: 0.73, 1.01).
Conclusions
The association of hypercholesterolemia with better outcomes highlights a major challenge in observational analyses. Our results suggest this paradox may result from confounding due to other clinical characteristics, impact of statin treatment, and perhaps most importantly, the fact that previously diagnosed hypercholesterolemia is a marker for patients with more prior medical contact. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (302.3 KB).
References
- 1. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986; 2(8513): 933–936. [DOI] [PubMed] [Google Scholar]
- 2. Pekkanen J, Linn S, Heiss G, et al. Ten‐year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322(24): 1700–1707. [DOI] [PubMed] [Google Scholar]
- 3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–1389. [PubMed] [Google Scholar]
- 4. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360(9326): 7–22. [DOI] [PubMed] [Google Scholar]
- 5. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST‐segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101(22): 2557–2567. [DOI] [PubMed] [Google Scholar]
- 6. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163(19): 2345–2353. [DOI] [PubMed] [Google Scholar]
- 7. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105(12): 1446–1452. [DOI] [PubMed] [Google Scholar]
- 8. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140(11): 857–866. [DOI] [PubMed] [Google Scholar]
- 9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non‐ST‐segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106(14): 1893–1900. [DOI] [PubMed] [Google Scholar]
- 10.CRUSADE National Quality Initiative Web Site. Available at: www.crusadeqi.com. Accessed November 14, 2007.
- 11. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42(1): 121–130. [PubMed] [Google Scholar]
- 12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–1622. [DOI] [PubMed] [Google Scholar]
- 13. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–1504. [DOI] [PubMed] [Google Scholar]
- 14. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001–1009. [DOI] [PubMed] [Google Scholar]
- 15. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301–1307. [DOI] [PubMed] [Google Scholar]
- 16. Pucci A, Sheiban I, Formato L, et al. In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis 2007; 194(1): 189–195. [DOI] [PubMed] [Google Scholar]